Fig. 4. Characteristics of antifungal treatment outcomes in patients in the C. albicans and non-albicans groups. (A) Outcomes of antifungal treatment (percentage of patients showing more than 50% improvement in pain as determined by the NRS at the first visit). (B) Duration of treatment with antifungal agents in patients in the C. albicans and non-albicans groups. (C) Disease duration according to antifungal treatment outcomes in the C. albicans group. NRS, numerical rating scale; C. albicans, Candida albicans. *p<0.05, **p<0.01, p-values were obtained by Pearson's chi-square test and Mann-Whitney U test.

J Oral Med Pain 2022;47:126-34 https://doi.org/10.14476/jomp.2022.47.3.126

© 2022 J Oral Med Pain